Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Infection-related arthritis
•
General Rheumatology
•
Infectious Disease
•
Infection Prevention and Control
In patients taking biologics who are planning joint replacement and are known MRSA carriers do you perform decolonization prior to surgery?
Related Questions
How often do you see bony erosions in patients with Lyme arthritis?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
Do you find HZV titers useful in diagnosing shingles sine herpete?
How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?
Is there any role for administering another course of recombinant zoster vaccine (shingrx) in a previously vaccinated patient with RA, who is in clinical remission on Jak inhibitor but has had a breakthrough shingles infection?
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
